Trial Profile
PSMA-based 18F-DCFPyL PET/CT and PET/MRI Pilot Studies in Prostate Cancer
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 21 Nov 2023
Price :
$35
*
At a glance
- Drugs Piflufolastat F18 (Primary)
- Indications Prostate cancer
- Focus Biomarker; Diagnostic use
- 14 Nov 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 14 Nov 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 12 Jul 2022 Planned number of patients changed from 36 to 104.